SlideShare una empresa de Scribd logo
1 de 23
Descargar para leer sin conexión
Primary Systemic Therapy:
Beginning the Journey
Beth Overmoyer MD, FACP
Director, Inflammatory Breast Cancer Program
1st Annual IBC Patient Forum
Dana Farber Cancer Institute
May 13, 2017
Historical Perspective of IBC
• The historical identification of IBC is important as a reminder of the
acceptance of classic clinical criteria that differentiates the disease
from other forms of locally advanced breast cancer
• 1814 – Sir Charles Bell described a grave prognosis associated with
breast cancer when the following characteristics are present:
• “when a purple color is on the skin over the tumor accompanied
by shooting pains it is a very unpropitious beginning”
• Lee and Tannenbaum (1924) – “inflammatory breast cancer”
IBC – A Distinct Subtype of Breast Cancer
Distinct subtype of breast cancer
• Definitive or pathologic
diagnostic criteria do not
exist
• “Clinical diagnosis” fraught
with potential problems,
both underestimating and
overestimating the
diagnosis
• Seer 2004-7: 2-yr BCS
• IBC = 84%
• LABC = 91%
• 43% higher risk of breast cancer death in
IBC vs. LABC
• German study: 4.5x greater risk of
dying within 5 years
Diessner Arch Gyn Obs 2015;292:655; Anderson WF, JCO 21:2254, 2003
IBC
LABC
• 1-5% incidence in US
• Difficulty in tracking the disease due to variation in diagnostic criteria
over time
• Underestimate incidence
Clinical definition with confirmed breast cancer: Rapid onset – 3 – 6 mo
• Erythema > 1/3 breast
• Edema (peau d’orange)
• Often warm breast, pain
• Breast enlargement – often without a mass
• Highly metastatic:
35% metastasis at presentation
Clinical Presentation - IBC
Clinical Diagnosis of IBC
• Tumor emboli in dermal lymphatics without classical signs is not
considered IBC
• The presence of dermal lymphatic invasion is not necessary for
the diagnosis of IBC
“Trimodality” Therapy: Importance of pCR
Primary
Systemic Therapy
Mastectomy +
Axillary LN Dissection
Radiation to Chest Wall
and Regional LN
Adjuvant Endocrine Rx (HR+)
+/or Trastuzumab (HER2+)
Nakhlis 2016
Overall survival
86%
51%
Time to tumor recurrence
79%
33%
Retrospective Studies of Preoperative
Chemotherapy for IBC
No.
IBC
Chemotherapy RR Median
Survival
Italy 68 CAF or CEF / CMF pCR: 3% 4 yr.
U Penn 52 CMF +/- CAF pCR: 12% NR
France 120 FEC-HD pCR: 15% 5 yr.
British Columbia 308 CT v intensive CT (+ T) pCR:
28% v 33%
3.2 yr.
MD Anderson 240 FAC v FAC + T pCR:
10% v 25%
3.4 v 4.3 yr
Primary chemotherapy backbone = anthracycline and taxane
Dose-Dense versus Conventional Preoperative
Chemotherapy (AGO-1) – Overall ≠ IBC
• 668 patients with locally advanced breast cancer
• Overall group benefitted from intensive
chemotherapy:
• Improved pCR – 18% vs 10%
• Improved time to disease recurrence
• Improved overall survival
Untch M JCO 2009; 27:2938
• 100 IBC
• No difference with intensity of chemotherapy:
• No difference in pCR – 12% vs 10%
• No difference in time to disease recurrence
• No difference in overall survival
≠
pCR Rates in SWOG 0012: Standard AC versus
“Continuous” AC
Georgiana K. Ellis et al. JCO 2011;29:1014-1021
• 356 Overall vs 111 IBC (31%)
• Overall: no difference in outcome
• Higher pCR in IBC with continuous dosing of chemotherapy – 27% vs 13%
Finding Therapeutic Targets in IBC
•HER-2
•Angiogenesis
•JAK2-STAT3
Finding Therapeutic Targets in IBC
•Targeting HER-2
•Angiogenesis
•JAK2-STAT3
NOAH – IBC Experience
64% v 24%
74% v 44%
5-YR EFS
5-YR OS
Doxorubicin
60mg/m2 →
Paclitaxel
150mg/m2 q21d x 3
Paclitaxel
175mg/m2 q21d x 4
CMF x 3
Subset Analysis
• 61 / 228 pts with IBC,
HER2+
• pCR = 48 % with
trastuzumab
•13% without trastuzumab
Gianni L. Lancet Oncol 2014 15:640
Anti-HER2 Therapy
Trypheana (13/225
= 6% IBC)
FEC+HP x 3 →T+HP x 3
(N=73)
FEC x 3 → T+HP x 3
(N=75)
TCH+P x 6
(N=77)
IBC 5(7%) 4(5%) 4(5%)
tpCR 41(56%) 41(55%) 48(64%)
NeoSphere
(29/417 = 7% IBC)
T+D (N=107) T+D+P (N=107) T+P (N=107) P+D (N=96)
IBC* 7 (7%) 10 (9%) 7 (7%) 5 (5%)
tpCR (all) 23 (22%) 42 (40%) 12 (11%) 17 (18%)
5y –DFS 81% 84% 80% 75%
Gianni Lancet Oncol 2012;13:25-32; Schneeweiss Ann Oncol 2013;2278-84; Gianni Lancet Oncol 2016; Gianni Lancet Oncol 2012;
Boussen, JCO 2010; Untch Lancet Onc 2012.
Investigating lapatinib Regimen Number enrolled pCR
MDACC Lapatinib +
paclitaxel
32 3/17 (18%)
GeparQuinto EC→D
(L v H)
82/620 =13% IBC 23% v 30% (p=0.04)
Odds ratio IBC = 0.72 (NS)
Run In Phase – Day 1 week 1 (breast biopsy #1)
Pertuzumab IV 840 mg loading dose Trastuzumab IV 4 mg/kg loading
dose
Treatment Phase – Day 8 week 2 (breast biopsy #2)
Trastuzumab IV 2mg/kg weekly and paclitaxel 80 mg/m2 IV weekly x 16 weeks.
Day 21 week 4
Continue trastuzumab and paclitaxel as above and begin pertuzumab 420 mg IV
every 21 days for 5 doses
Modified radical mastectomy
(assess residual disease)
Post-operative Treatment:
Doxorubicin 60 mg/m2 IV and cyclophosphamide 600 mg/m2 IV every 3 weeks x 4 cycles*
Followed by trastuzumab 6 mg/kg and pertuzumab 420 mg every 21 days x 8 months**
(loading dose given first after AC completed)
Radiation Therapy
Endocrine therapy if HR+
*Optional
**Metastatic disease (nodal disease only):
continue on pertuzumab + trastuzumab
until disease progression
Primary Objective: pCR
• Accept benefit if > 8/ 27
pts have pCR
NCI-2013-01110, NCT0179619712-497; Genentech, IBC Network - sponsor
Hypothesis:
Can we limit the amount
of chemotherapy and
maximize the HER2-
directed therapy in the
treatment of HER2+ IBC ?
Finding Therapeutic Targets in IBC
•Targeting HER-2
•Angiogenesis
•JAK2-STAT3
Angiogenesis and Lymphangiogenesis in IBC
• IBC makes its own blood supply and
lymphatic supply throughout the
breast
• Increased expression of
angiogenesis related genes
• Increased expression of
lymphangiogenesis related genes
• Is this “encircling
lymphovasculogenesis” or
lymphovascular invasion ?
Colpaert CG, Br J Ca 2003;88:718; Van der Auwera Clin Can Res 2005;11:7637
Angiogenesis in IBC: Is it a Useful Target ?
Addition of Anti-angiogenic Agents to Pre-operative Chemotherapy
Treatment Number Stage pCR Median
DFS (III)
Correlatives
SU5416, doxorubicin 17 III or IV 0 32 mo DCE/MRI –
(Kep) – 58%
(p=0.033)
Bevacizumab,
docetaxel,
doxorubicin
21 (1 LABC) III or IV 1 (5%) 25.3 mo DCE-MRI –
(Ktrans) – 34%
(p=.003)
BEVERLY-1 (FEC(B) x
4 → D(B) x 4)
100 III 19 (19%) 53 mo CTC not
associated with
pCR
BEVERLY-2 (FEC(B) x
4 → D(B+H) x 4)
52 III 33 (64%) NA CTC not
associated with
pCR
Overmoyer CCR 2007; Wedam JCO 2006; Bertucci 2016; Pierga 2012
Eribulin and Normalization of Vasculature
Region of Interest (ROI) Ktrans (1/min/1000)
Pre-Eribulin Post-Eribulin (d 8)
#1 ROI 78.1 115.2
#2 ROI 47.5 71.4
• Eribulin effects on mice:
• Improves blood flow to inside of tumor
• Increased overall tumor blood flow
• Changes in expression of genes for blood
vessel formation and cancer survival
• In IBC – investigate eribulin’s effect on tumor
blood flow
• Also investigate expression on genes for
blood vessel formation and cancer survival
2
1
Agoulnik Vasc Cell 2014.; Funahashi Cancer Sci 2014; Yoshida Br J Cancer 2014.; Dezso PLoS One 2014.; Overmoyer SABCS 2016.
2
1
Pre-treatment breast biopsy #1
Eribulin x 1 (cycle 1 day 1)
Breast biopsy #2: 1 wk after eribulin
(cycle 1 day 8)
Eribulin q 3 wks x 3 cycles
dd AC q 2 wks x 4 cycles
Mastectomy (harvest residual tumor)
Radiation therapy + endocrine therapy
Imaging subset study
Pre-treatment
breast DCE-MRI
1 wk after eribulin
(c1,d8) breast DCE-
MRI
Eribulin
1.4mg/m2 IV
d1,d8 q21d x 4
cycles
Doxorubicin 60
mg/m2 +
cyclophosphamide
600 mg/m2 IV q2w x
4 cycles
Overview
• Primary Objective: pCR rate
• Two-stage design:
• Reject if pCR is < 15%
• Accept if pCR > 30%
• > 2/16 pCR – go forward
• Accept benefit if > 5/ 25 pts
have pCR
NCI-2016-00329, NCT0262397215-292; Eisai-sponsor
Finding Therapeutic Targets in IBC
•Targeting HER-2
•Angiogenesis
•JAK2-STAT3
Slides curtesy of Kornelia Polyak MD, PhD
N=64
(50 +)
Ruxolitinib x 7
days
(N=32)
Ruxolitinib x 7d +
Paclitaxel x 1 wk
(N=32)
Paclitaxel x 12
weeks (N=16)
Ruxolitinib +
Paclitaxel x 12
weeks (N=16)
Ruxolitinib +
Paclitaxel x 11
weeks (N=32)
dd doxorubicin/cyclophosphamide x
4 cycles (N=64)
Modified radical mastectomy
Radiation therapy
Pre-treatment biopsy #1
Post-run-in biopsy #2
Primary:
Pharmacodynamic
Secondary:
Clinical
TBCRC 039 - SCHEME
Sponsored by Incyte, and
Inflammatory Breast Cancer Research Foundation
Primary Systemic Therapy for IBC:
Beginning the Journey
• IBC is inoperable at the time of diagnosis, therefore initial therapy with
“systemic treatment” is indicated.
• IBC is relatively chemo-resistant, therefore identifying therapeutic targets is
critical.
• We must focus our efforts on designing clinical trials specifically for IBC
• Inclusion of IBC patients into LABC trials will dilute the interpretation of
outcome
• Incorporate translational components
• Identify biologic markers that confirm the diagnosis, not just rely on “clinical
features” that are not consistent.

Más contenido relacionado

La actualidad más candente

Management of endometrial carcinoma
Management of endometrial carcinomaManagement of endometrial carcinoma
Management of endometrial carcinomaSailendra Parida
 
Pathology of Endometrial cancer 2022.pptx
Pathology of Endometrial cancer 2022.pptxPathology of Endometrial cancer 2022.pptx
Pathology of Endometrial cancer 2022.pptxDr ABU SURAIH SAKHRI
 
CARCINOMA OVARY- EARLY STAGE MANAGEMENT
CARCINOMA OVARY- EARLY STAGE MANAGEMENTCARCINOMA OVARY- EARLY STAGE MANAGEMENT
CARCINOMA OVARY- EARLY STAGE MANAGEMENTNabeel Yahiya
 
Post Mastectomy Radiotherapy
Post Mastectomy RadiotherapyPost Mastectomy Radiotherapy
Post Mastectomy Radiotherapyfondas vakalis
 
Locally advanced ca breast LABC
Locally advanced ca breast LABCLocally advanced ca breast LABC
Locally advanced ca breast LABCDr.Rashmi Yadav
 
UTERINE LEIOMYOSARCOMA
UTERINE LEIOMYOSARCOMAUTERINE LEIOMYOSARCOMA
UTERINE LEIOMYOSARCOMApaviarun
 
Radiotherapy in gynaecology
Radiotherapy in gynaecologyRadiotherapy in gynaecology
Radiotherapy in gynaecologydrmcbansal
 
History of radical hysterectomy for cancer cervix
History of radical hysterectomy for cancer cervixHistory of radical hysterectomy for cancer cervix
History of radical hysterectomy for cancer cervixSakshi Mundra
 
Triple Negative Breast Cancer
Triple Negative Breast CancerTriple Negative Breast Cancer
Triple Negative Breast CancerMohamed Abdulla
 
Update on Management of Breast cancer
Update on Management of Breast cancerUpdate on Management of Breast cancer
Update on Management of Breast cancerMakafui Yigah
 
LANDMARK TRIALS IN BREAST CANCER
LANDMARK TRIALS IN BREAST CANCERLANDMARK TRIALS IN BREAST CANCER
LANDMARK TRIALS IN BREAST CANCERAaditya Prakash
 
Locally advanced breast cancer management
Locally advanced breast cancer managementLocally advanced breast cancer management
Locally advanced breast cancer managementadityasingla007
 
Neoadjuvant and hormonal therapy in Breast cancer - Yousef El-Ayman
Neoadjuvant and hormonal therapy in Breast cancer - Yousef El-AymanNeoadjuvant and hormonal therapy in Breast cancer - Yousef El-Ayman
Neoadjuvant and hormonal therapy in Breast cancer - Yousef El-Aymansurgizag
 
RADIOTHERAPY FOR ENDOMETRIUM AND CERVICAL CANCERS
RADIOTHERAPY FOR ENDOMETRIUM AND CERVICAL CANCERSRADIOTHERAPY FOR ENDOMETRIUM AND CERVICAL CANCERS
RADIOTHERAPY FOR ENDOMETRIUM AND CERVICAL CANCERSKanhu Charan
 

La actualidad más candente (20)

Anal cancer
Anal cancerAnal cancer
Anal cancer
 
Management of endometrial carcinoma
Management of endometrial carcinomaManagement of endometrial carcinoma
Management of endometrial carcinoma
 
Inflammatory Breast Cancer (IBC) Information
Inflammatory Breast Cancer (IBC) InformationInflammatory Breast Cancer (IBC) Information
Inflammatory Breast Cancer (IBC) Information
 
Pathology of Endometrial cancer 2022.pptx
Pathology of Endometrial cancer 2022.pptxPathology of Endometrial cancer 2022.pptx
Pathology of Endometrial cancer 2022.pptx
 
CARCINOMA OVARY- EARLY STAGE MANAGEMENT
CARCINOMA OVARY- EARLY STAGE MANAGEMENTCARCINOMA OVARY- EARLY STAGE MANAGEMENT
CARCINOMA OVARY- EARLY STAGE MANAGEMENT
 
Post Mastectomy Radiotherapy
Post Mastectomy RadiotherapyPost Mastectomy Radiotherapy
Post Mastectomy Radiotherapy
 
Locally advanced ca breast LABC
Locally advanced ca breast LABCLocally advanced ca breast LABC
Locally advanced ca breast LABC
 
UTERINE LEIOMYOSARCOMA
UTERINE LEIOMYOSARCOMAUTERINE LEIOMYOSARCOMA
UTERINE LEIOMYOSARCOMA
 
Radiotherapy in gynaecology
Radiotherapy in gynaecologyRadiotherapy in gynaecology
Radiotherapy in gynaecology
 
History of radical hysterectomy for cancer cervix
History of radical hysterectomy for cancer cervixHistory of radical hysterectomy for cancer cervix
History of radical hysterectomy for cancer cervix
 
Triple Negative Breast Cancer
Triple Negative Breast CancerTriple Negative Breast Cancer
Triple Negative Breast Cancer
 
TNT MAYO.pptx
TNT MAYO.pptxTNT MAYO.pptx
TNT MAYO.pptx
 
Transforming Treatment in Ovarian Cancer
Transforming Treatment in Ovarian CancerTransforming Treatment in Ovarian Cancer
Transforming Treatment in Ovarian Cancer
 
Update on Management of Breast cancer
Update on Management of Breast cancerUpdate on Management of Breast cancer
Update on Management of Breast cancer
 
LANDMARK TRIALS IN BREAST CANCER
LANDMARK TRIALS IN BREAST CANCERLANDMARK TRIALS IN BREAST CANCER
LANDMARK TRIALS IN BREAST CANCER
 
Cervical carcinoma
Cervical carcinomaCervical carcinoma
Cervical carcinoma
 
Radiation for Gastric Cancer
Radiation for Gastric CancerRadiation for Gastric Cancer
Radiation for Gastric Cancer
 
Locally advanced breast cancer management
Locally advanced breast cancer managementLocally advanced breast cancer management
Locally advanced breast cancer management
 
Neoadjuvant and hormonal therapy in Breast cancer - Yousef El-Ayman
Neoadjuvant and hormonal therapy in Breast cancer - Yousef El-AymanNeoadjuvant and hormonal therapy in Breast cancer - Yousef El-Ayman
Neoadjuvant and hormonal therapy in Breast cancer - Yousef El-Ayman
 
RADIOTHERAPY FOR ENDOMETRIUM AND CERVICAL CANCERS
RADIOTHERAPY FOR ENDOMETRIUM AND CERVICAL CANCERSRADIOTHERAPY FOR ENDOMETRIUM AND CERVICAL CANCERS
RADIOTHERAPY FOR ENDOMETRIUM AND CERVICAL CANCERS
 

Similar a Primary Systemic Therapy for Inflammatory Breast Cancer

Noa Efrat Ben Baruch : Neo-adjuvant treatment in breast cancer
Noa Efrat Ben Baruch : Neo-adjuvant treatment in breast cancerNoa Efrat Ben Baruch : Neo-adjuvant treatment in breast cancer
Noa Efrat Ben Baruch : Neo-adjuvant treatment in breast cancerbreastcancerupdatecongress
 
Cervical cancer
Cervical cancerCervical cancer
Cervical cancermadurai
 
How I treat Relapsed Ca Ovary
How I treat Relapsed Ca OvaryHow I treat Relapsed Ca Ovary
How I treat Relapsed Ca OvaryChandan K Das
 
Ovarian Cancer 101
Ovarian Cancer 101Ovarian Cancer 101
Ovarian Cancer 101bkling
 
Colorectal Cancer Research & Treatment News - recap from the May 2014 ASCO co...
Colorectal Cancer Research & Treatment News - recap from the May 2014 ASCO co...Colorectal Cancer Research & Treatment News - recap from the May 2014 ASCO co...
Colorectal Cancer Research & Treatment News - recap from the May 2014 ASCO co...Fight Colorectal Cancer
 
Report Back from San Antonio Breast Cancer Symposium (SABCS 2022)
Report Back from San Antonio Breast Cancer Symposium (SABCS 2022)Report Back from San Antonio Breast Cancer Symposium (SABCS 2022)
Report Back from San Antonio Breast Cancer Symposium (SABCS 2022)bkling
 
BALKAN MCO 2011 - A. Eniu - How to optimize systemic therapy in LABC
BALKAN MCO 2011 - A. Eniu - How to optimize systemic therapy in LABC BALKAN MCO 2011 - A. Eniu - How to optimize systemic therapy in LABC
BALKAN MCO 2011 - A. Eniu - How to optimize systemic therapy in LABC European School of Oncology
 
Jean Yves Pierga ASCO 2015
Jean Yves Pierga ASCO 2015Jean Yves Pierga ASCO 2015
Jean Yves Pierga ASCO 2015SiRIC_Curie
 
Research Update on MBC
Research Update on MBCResearch Update on MBC
Research Update on MBCbkling
 
Post mastectomy Radiotherapy with trails
Post mastectomy Radiotherapy with trailsPost mastectomy Radiotherapy with trails
Post mastectomy Radiotherapy with trailsAnban Bala
 
NSCLC housestaff
NSCLC housestaffNSCLC housestaff
NSCLC housestaffderosaMSKCC
 
Managment of Cervical Cancer
Managment of Cervical CancerManagment of Cervical Cancer
Managment of Cervical CancerAjay Sasidharan
 
Gi Cancer Symposium 2012 Report Presentation
Gi Cancer Symposium 2012 Report PresentationGi Cancer Symposium 2012 Report Presentation
Gi Cancer Symposium 2012 Report PresentationFight Colorectal Cancer
 
Product Visual Guide
Product Visual GuideProduct Visual Guide
Product Visual GuideManas Tandon
 
Hipec for metastatic colorectal cancers
Hipec for metastatic colorectal cancersHipec for metastatic colorectal cancers
Hipec for metastatic colorectal cancersPriyanka Malekar
 
Rectal cancer debate: Chemoradiation
Rectal cancer debate: ChemoradiationRectal cancer debate: Chemoradiation
Rectal cancer debate: ChemoradiationAshutosh Mukherji
 
CORALLEEN phase 2 trial: Neoadjuvant Ribociclib plus Letrozole in Early Stage...
CORALLEEN phase 2 trial: Neoadjuvant Ribociclib plus Letrozole in Early Stage...CORALLEEN phase 2 trial: Neoadjuvant Ribociclib plus Letrozole in Early Stage...
CORALLEEN phase 2 trial: Neoadjuvant Ribociclib plus Letrozole in Early Stage...mutahir2
 
ADJUTANT RADIOTHERAPY IN BREAST CANCER
ADJUTANT RADIOTHERAPY IN BREAST CANCER ADJUTANT RADIOTHERAPY IN BREAST CANCER
ADJUTANT RADIOTHERAPY IN BREAST CANCER Nora Essam
 
Report Back from 2023 San Antonio Breast Cancer Symposium (SABCS)
Report Back from 2023 San Antonio Breast Cancer Symposium (SABCS)Report Back from 2023 San Antonio Breast Cancer Symposium (SABCS)
Report Back from 2023 San Antonio Breast Cancer Symposium (SABCS)bkling
 
J.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the artJ.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the artEuropean School of Oncology
 

Similar a Primary Systemic Therapy for Inflammatory Breast Cancer (20)

Noa Efrat Ben Baruch : Neo-adjuvant treatment in breast cancer
Noa Efrat Ben Baruch : Neo-adjuvant treatment in breast cancerNoa Efrat Ben Baruch : Neo-adjuvant treatment in breast cancer
Noa Efrat Ben Baruch : Neo-adjuvant treatment in breast cancer
 
Cervical cancer
Cervical cancerCervical cancer
Cervical cancer
 
How I treat Relapsed Ca Ovary
How I treat Relapsed Ca OvaryHow I treat Relapsed Ca Ovary
How I treat Relapsed Ca Ovary
 
Ovarian Cancer 101
Ovarian Cancer 101Ovarian Cancer 101
Ovarian Cancer 101
 
Colorectal Cancer Research & Treatment News - recap from the May 2014 ASCO co...
Colorectal Cancer Research & Treatment News - recap from the May 2014 ASCO co...Colorectal Cancer Research & Treatment News - recap from the May 2014 ASCO co...
Colorectal Cancer Research & Treatment News - recap from the May 2014 ASCO co...
 
Report Back from San Antonio Breast Cancer Symposium (SABCS 2022)
Report Back from San Antonio Breast Cancer Symposium (SABCS 2022)Report Back from San Antonio Breast Cancer Symposium (SABCS 2022)
Report Back from San Antonio Breast Cancer Symposium (SABCS 2022)
 
BALKAN MCO 2011 - A. Eniu - How to optimize systemic therapy in LABC
BALKAN MCO 2011 - A. Eniu - How to optimize systemic therapy in LABC BALKAN MCO 2011 - A. Eniu - How to optimize systemic therapy in LABC
BALKAN MCO 2011 - A. Eniu - How to optimize systemic therapy in LABC
 
Jean Yves Pierga ASCO 2015
Jean Yves Pierga ASCO 2015Jean Yves Pierga ASCO 2015
Jean Yves Pierga ASCO 2015
 
Research Update on MBC
Research Update on MBCResearch Update on MBC
Research Update on MBC
 
Post mastectomy Radiotherapy with trails
Post mastectomy Radiotherapy with trailsPost mastectomy Radiotherapy with trails
Post mastectomy Radiotherapy with trails
 
NSCLC housestaff
NSCLC housestaffNSCLC housestaff
NSCLC housestaff
 
Managment of Cervical Cancer
Managment of Cervical CancerManagment of Cervical Cancer
Managment of Cervical Cancer
 
Gi Cancer Symposium 2012 Report Presentation
Gi Cancer Symposium 2012 Report PresentationGi Cancer Symposium 2012 Report Presentation
Gi Cancer Symposium 2012 Report Presentation
 
Product Visual Guide
Product Visual GuideProduct Visual Guide
Product Visual Guide
 
Hipec for metastatic colorectal cancers
Hipec for metastatic colorectal cancersHipec for metastatic colorectal cancers
Hipec for metastatic colorectal cancers
 
Rectal cancer debate: Chemoradiation
Rectal cancer debate: ChemoradiationRectal cancer debate: Chemoradiation
Rectal cancer debate: Chemoradiation
 
CORALLEEN phase 2 trial: Neoadjuvant Ribociclib plus Letrozole in Early Stage...
CORALLEEN phase 2 trial: Neoadjuvant Ribociclib plus Letrozole in Early Stage...CORALLEEN phase 2 trial: Neoadjuvant Ribociclib plus Letrozole in Early Stage...
CORALLEEN phase 2 trial: Neoadjuvant Ribociclib plus Letrozole in Early Stage...
 
ADJUTANT RADIOTHERAPY IN BREAST CANCER
ADJUTANT RADIOTHERAPY IN BREAST CANCER ADJUTANT RADIOTHERAPY IN BREAST CANCER
ADJUTANT RADIOTHERAPY IN BREAST CANCER
 
Report Back from 2023 San Antonio Breast Cancer Symposium (SABCS)
Report Back from 2023 San Antonio Breast Cancer Symposium (SABCS)Report Back from 2023 San Antonio Breast Cancer Symposium (SABCS)
Report Back from 2023 San Antonio Breast Cancer Symposium (SABCS)
 
J.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the artJ.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the art
 

Más de Dana-Farber Cancer Institute

Personal Finance Tips for Young Adults with Cancer
Personal Finance Tips for Young Adults with Cancer Personal Finance Tips for Young Adults with Cancer
Personal Finance Tips for Young Adults with Cancer Dana-Farber Cancer Institute
 
How are Adult and Childhood Leukemia Alike and Different?
How are Adult and Childhood Leukemia Alike and Different?How are Adult and Childhood Leukemia Alike and Different?
How are Adult and Childhood Leukemia Alike and Different?Dana-Farber Cancer Institute
 
Research in the Program for Young Women with Breast Cancer: Past, Present and...
Research in the Program for Young Women with Breast Cancer: Past, Present and...Research in the Program for Young Women with Breast Cancer: Past, Present and...
Research in the Program for Young Women with Breast Cancer: Past, Present and...Dana-Farber Cancer Institute
 
Clinical Trials for Metastatic HER2-positive Breast Cancer
Clinical Trials for Metastatic HER2-positive Breast CancerClinical Trials for Metastatic HER2-positive Breast Cancer
Clinical Trials for Metastatic HER2-positive Breast CancerDana-Farber Cancer Institute
 
Clinical Trials for Metastatic Triple-Negative Breast Cancer
Clinical Trials for Metastatic Triple-Negative Breast CancerClinical Trials for Metastatic Triple-Negative Breast Cancer
Clinical Trials for Metastatic Triple-Negative Breast CancerDana-Farber Cancer Institute
 
Surgery for Inflammatory Breast Cancer: How and Why
Surgery for Inflammatory Breast Cancer: How and WhySurgery for Inflammatory Breast Cancer: How and Why
Surgery for Inflammatory Breast Cancer: How and WhyDana-Farber Cancer Institute
 
7 Ways Integrative Therapies Can Help Cancer Patients
7 Ways Integrative Therapies Can Help Cancer Patients7 Ways Integrative Therapies Can Help Cancer Patients
7 Ways Integrative Therapies Can Help Cancer PatientsDana-Farber Cancer Institute
 

Más de Dana-Farber Cancer Institute (20)

Exercise Tips for Cancer Patients
Exercise Tips for Cancer Patients Exercise Tips for Cancer Patients
Exercise Tips for Cancer Patients
 
Personal Finance Tips for Young Adults with Cancer
Personal Finance Tips for Young Adults with Cancer Personal Finance Tips for Young Adults with Cancer
Personal Finance Tips for Young Adults with Cancer
 
5 Things to Know About Glioblastomas
5 Things to Know About Glioblastomas5 Things to Know About Glioblastomas
5 Things to Know About Glioblastomas
 
How are Adult and Childhood Leukemia Alike and Different?
How are Adult and Childhood Leukemia Alike and Different?How are Adult and Childhood Leukemia Alike and Different?
How are Adult and Childhood Leukemia Alike and Different?
 
Research in the Program for Young Women with Breast Cancer: Past, Present and...
Research in the Program for Young Women with Breast Cancer: Past, Present and...Research in the Program for Young Women with Breast Cancer: Past, Present and...
Research in the Program for Young Women with Breast Cancer: Past, Present and...
 
Clinical Trials for Metastatic HER2-positive Breast Cancer
Clinical Trials for Metastatic HER2-positive Breast CancerClinical Trials for Metastatic HER2-positive Breast Cancer
Clinical Trials for Metastatic HER2-positive Breast Cancer
 
Clinical Trials for Metastatic Triple-Negative Breast Cancer
Clinical Trials for Metastatic Triple-Negative Breast CancerClinical Trials for Metastatic Triple-Negative Breast Cancer
Clinical Trials for Metastatic Triple-Negative Breast Cancer
 
Healthy Living After A Breast Cancer Diagnosis
Healthy Living After A Breast Cancer DiagnosisHealthy Living After A Breast Cancer Diagnosis
Healthy Living After A Breast Cancer Diagnosis
 
Signs and Symptoms of Prostate Cancer
Signs and Symptoms of Prostate CancerSigns and Symptoms of Prostate Cancer
Signs and Symptoms of Prostate Cancer
 
6 Common Types of Pediatric Brain Tumors
6 Common Types of Pediatric Brain Tumors6 Common Types of Pediatric Brain Tumors
6 Common Types of Pediatric Brain Tumors
 
Soft Tissue Sarcomas: Symptoms and Risk Factors
Soft Tissue Sarcomas: Symptoms and Risk FactorsSoft Tissue Sarcomas: Symptoms and Risk Factors
Soft Tissue Sarcomas: Symptoms and Risk Factors
 
10 Tips for Easing Chemo-Related Fatigue
10 Tips for Easing Chemo-Related Fatigue10 Tips for Easing Chemo-Related Fatigue
10 Tips for Easing Chemo-Related Fatigue
 
Surgery for Inflammatory Breast Cancer: How and Why
Surgery for Inflammatory Breast Cancer: How and WhySurgery for Inflammatory Breast Cancer: How and Why
Surgery for Inflammatory Breast Cancer: How and Why
 
Radiation Therapy for Inflammatory Breast Cancer
Radiation Therapy for Inflammatory Breast CancerRadiation Therapy for Inflammatory Breast Cancer
Radiation Therapy for Inflammatory Breast Cancer
 
What Cancers Should Men Be Screened For?
What Cancers Should Men Be Screened For?What Cancers Should Men Be Screened For?
What Cancers Should Men Be Screened For?
 
Five Common Types of Brain Tumors
Five Common Types of Brain TumorsFive Common Types of Brain Tumors
Five Common Types of Brain Tumors
 
Signs and Symptoms of Multiple Myeloma
Signs and Symptoms of Multiple MyelomaSigns and Symptoms of Multiple Myeloma
Signs and Symptoms of Multiple Myeloma
 
7 Ways Integrative Therapies Can Help Cancer Patients
7 Ways Integrative Therapies Can Help Cancer Patients7 Ways Integrative Therapies Can Help Cancer Patients
7 Ways Integrative Therapies Can Help Cancer Patients
 
Five Things You Need to Know About Colon Cancer
Five Things You Need to Know About Colon CancerFive Things You Need to Know About Colon Cancer
Five Things You Need to Know About Colon Cancer
 
What You Should Know About Cervical Cancer
What You Should Know About Cervical CancerWhat You Should Know About Cervical Cancer
What You Should Know About Cervical Cancer
 

Último

Health literacies in marginalised communities LILAC 24.pptx
Health literacies in marginalised communities LILAC 24.pptxHealth literacies in marginalised communities LILAC 24.pptx
Health literacies in marginalised communities LILAC 24.pptxPamela McKinney
 
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdfDolisha Warbi
 
person with disability and pwd act ppt.pptx
person with disability and pwd act ppt.pptxperson with disability and pwd act ppt.pptx
person with disability and pwd act ppt.pptxMUKESH PADMANABHAN
 
Artificial Intelligence in Healthcare: Challenges, Risks, Benefits
Artificial Intelligence in Healthcare: Challenges, Risks, BenefitsArtificial Intelligence in Healthcare: Challenges, Risks, Benefits
Artificial Intelligence in Healthcare: Challenges, Risks, BenefitsIris Thiele Isip-Tan
 
Anatomy Shelf Notevbhhhhhhhhhhhhhhhs.pdf
Anatomy Shelf Notevbhhhhhhhhhhhhhhhs.pdfAnatomy Shelf Notevbhhhhhhhhhhhhhhhs.pdf
Anatomy Shelf Notevbhhhhhhhhhhhhhhhs.pdfhezamzaki1
 
Assisted Living Care Residency - PapayaCare
Assisted Living Care Residency - PapayaCareAssisted Living Care Residency - PapayaCare
Assisted Living Care Residency - PapayaCareratilalthakkar704
 
ARTHRITIS.pptx Prepared by monika gopal Tutor
ARTHRITIS.pptx Prepared  by monika gopal TutorARTHRITIS.pptx Prepared  by monika gopal Tutor
ARTHRITIS.pptx Prepared by monika gopal TutorNehaKewat
 
Diseases of the Respiratory System (J00-J99),.pptx
Diseases of the Respiratory System (J00-J99),.pptxDiseases of the Respiratory System (J00-J99),.pptx
Diseases of the Respiratory System (J00-J99),.pptxEMADABATHINI PRABHU TEJA
 
EYE CANCER.pptx prepared by Neha kewat digital learning
EYE CANCER.pptx prepared by  Neha kewat digital learningEYE CANCER.pptx prepared by  Neha kewat digital learning
EYE CANCER.pptx prepared by Neha kewat digital learningNehaKewat
 
2024 Compliatric Webianr Series - Contracts and MOUs from a HRSA Perspective.pdf
2024 Compliatric Webianr Series - Contracts and MOUs from a HRSA Perspective.pdf2024 Compliatric Webianr Series - Contracts and MOUs from a HRSA Perspective.pdf
2024 Compliatric Webianr Series - Contracts and MOUs from a HRSA Perspective.pdfCompliatric Where Compliance Happens
 
LARYNGEAL CANCER.pptx Prepared by Neha Kewat
LARYNGEAL CANCER.pptx  Prepared by Neha KewatLARYNGEAL CANCER.pptx  Prepared by Neha Kewat
LARYNGEAL CANCER.pptx Prepared by Neha KewatNehaKewat
 
Hematinics and Erythropoietin- Pharmacology of Hematinics
Hematinics and Erythropoietin- Pharmacology of HematinicsHematinics and Erythropoietin- Pharmacology of Hematinics
Hematinics and Erythropoietin- Pharmacology of Hematinicsnetraangadi2
 
Introduction to Evaluation and Skin Benefits
Introduction to Evaluation and Skin BenefitsIntroduction to Evaluation and Skin Benefits
Introduction to Evaluation and Skin Benefitssahilgabhane29
 
Empathy Is a Stress Response - Choose Compassion instead
Empathy Is a Stress Response - Choose Compassion insteadEmpathy Is a Stress Response - Choose Compassion instead
Empathy Is a Stress Response - Choose Compassion insteadAlex Clapson
 
Understanding Warts and Moles: Differences, Types, and Common Locations
Understanding Warts and Moles: Differences, Types, and Common LocationsUnderstanding Warts and Moles: Differences, Types, and Common Locations
Understanding Warts and Moles: Differences, Types, and Common LocationsNeha Sharma
 
NEONATAL RESPIRATORY CARE FROM A PHYSIO POV.pptx
NEONATAL RESPIRATORY CARE FROM A PHYSIO POV.pptxNEONATAL RESPIRATORY CARE FROM A PHYSIO POV.pptx
NEONATAL RESPIRATORY CARE FROM A PHYSIO POV.pptxHanineHassan2
 
Pharmacovigilance audits inspections.pptx
Pharmacovigilance audits inspections.pptxPharmacovigilance audits inspections.pptx
Pharmacovigilance audits inspections.pptxCliniminds India
 

Último (20)

Health literacies in marginalised communities LILAC 24.pptx
Health literacies in marginalised communities LILAC 24.pptxHealth literacies in marginalised communities LILAC 24.pptx
Health literacies in marginalised communities LILAC 24.pptx
 
Annual Training
Annual TrainingAnnual Training
Annual Training
 
SCOPE OF CRITICAL CARE ORGANIZATION
SCOPE OF CRITICAL CARE ORGANIZATIONSCOPE OF CRITICAL CARE ORGANIZATION
SCOPE OF CRITICAL CARE ORGANIZATION
 
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf
 
person with disability and pwd act ppt.pptx
person with disability and pwd act ppt.pptxperson with disability and pwd act ppt.pptx
person with disability and pwd act ppt.pptx
 
Artificial Intelligence in Healthcare: Challenges, Risks, Benefits
Artificial Intelligence in Healthcare: Challenges, Risks, BenefitsArtificial Intelligence in Healthcare: Challenges, Risks, Benefits
Artificial Intelligence in Healthcare: Challenges, Risks, Benefits
 
Anatomy Shelf Notevbhhhhhhhhhhhhhhhs.pdf
Anatomy Shelf Notevbhhhhhhhhhhhhhhhs.pdfAnatomy Shelf Notevbhhhhhhhhhhhhhhhs.pdf
Anatomy Shelf Notevbhhhhhhhhhhhhhhhs.pdf
 
Assisted Living Care Residency - PapayaCare
Assisted Living Care Residency - PapayaCareAssisted Living Care Residency - PapayaCare
Assisted Living Care Residency - PapayaCare
 
ARTHRITIS.pptx Prepared by monika gopal Tutor
ARTHRITIS.pptx Prepared  by monika gopal TutorARTHRITIS.pptx Prepared  by monika gopal Tutor
ARTHRITIS.pptx Prepared by monika gopal Tutor
 
Diseases of the Respiratory System (J00-J99),.pptx
Diseases of the Respiratory System (J00-J99),.pptxDiseases of the Respiratory System (J00-J99),.pptx
Diseases of the Respiratory System (J00-J99),.pptx
 
EYE CANCER.pptx prepared by Neha kewat digital learning
EYE CANCER.pptx prepared by  Neha kewat digital learningEYE CANCER.pptx prepared by  Neha kewat digital learning
EYE CANCER.pptx prepared by Neha kewat digital learning
 
2024 Compliatric Webianr Series - Contracts and MOUs from a HRSA Perspective.pdf
2024 Compliatric Webianr Series - Contracts and MOUs from a HRSA Perspective.pdf2024 Compliatric Webianr Series - Contracts and MOUs from a HRSA Perspective.pdf
2024 Compliatric Webianr Series - Contracts and MOUs from a HRSA Perspective.pdf
 
LARYNGEAL CANCER.pptx Prepared by Neha Kewat
LARYNGEAL CANCER.pptx  Prepared by Neha KewatLARYNGEAL CANCER.pptx  Prepared by Neha Kewat
LARYNGEAL CANCER.pptx Prepared by Neha Kewat
 
Hematinics and Erythropoietin- Pharmacology of Hematinics
Hematinics and Erythropoietin- Pharmacology of HematinicsHematinics and Erythropoietin- Pharmacology of Hematinics
Hematinics and Erythropoietin- Pharmacology of Hematinics
 
Introduction to Evaluation and Skin Benefits
Introduction to Evaluation and Skin BenefitsIntroduction to Evaluation and Skin Benefits
Introduction to Evaluation and Skin Benefits
 
Empathy Is a Stress Response - Choose Compassion instead
Empathy Is a Stress Response - Choose Compassion insteadEmpathy Is a Stress Response - Choose Compassion instead
Empathy Is a Stress Response - Choose Compassion instead
 
Understanding Warts and Moles: Differences, Types, and Common Locations
Understanding Warts and Moles: Differences, Types, and Common LocationsUnderstanding Warts and Moles: Differences, Types, and Common Locations
Understanding Warts and Moles: Differences, Types, and Common Locations
 
NEONATAL RESPIRATORY CARE FROM A PHYSIO POV.pptx
NEONATAL RESPIRATORY CARE FROM A PHYSIO POV.pptxNEONATAL RESPIRATORY CARE FROM A PHYSIO POV.pptx
NEONATAL RESPIRATORY CARE FROM A PHYSIO POV.pptx
 
Pharmacovigilance audits inspections.pptx
Pharmacovigilance audits inspections.pptxPharmacovigilance audits inspections.pptx
Pharmacovigilance audits inspections.pptx
 
Painting Rats White Angers Them to No End
Painting Rats White Angers Them to No EndPainting Rats White Angers Them to No End
Painting Rats White Angers Them to No End
 

Primary Systemic Therapy for Inflammatory Breast Cancer

  • 1. Primary Systemic Therapy: Beginning the Journey Beth Overmoyer MD, FACP Director, Inflammatory Breast Cancer Program 1st Annual IBC Patient Forum Dana Farber Cancer Institute May 13, 2017
  • 2. Historical Perspective of IBC • The historical identification of IBC is important as a reminder of the acceptance of classic clinical criteria that differentiates the disease from other forms of locally advanced breast cancer • 1814 – Sir Charles Bell described a grave prognosis associated with breast cancer when the following characteristics are present: • “when a purple color is on the skin over the tumor accompanied by shooting pains it is a very unpropitious beginning” • Lee and Tannenbaum (1924) – “inflammatory breast cancer”
  • 3. IBC – A Distinct Subtype of Breast Cancer Distinct subtype of breast cancer • Definitive or pathologic diagnostic criteria do not exist • “Clinical diagnosis” fraught with potential problems, both underestimating and overestimating the diagnosis • Seer 2004-7: 2-yr BCS • IBC = 84% • LABC = 91% • 43% higher risk of breast cancer death in IBC vs. LABC • German study: 4.5x greater risk of dying within 5 years Diessner Arch Gyn Obs 2015;292:655; Anderson WF, JCO 21:2254, 2003 IBC LABC
  • 4. • 1-5% incidence in US • Difficulty in tracking the disease due to variation in diagnostic criteria over time • Underestimate incidence Clinical definition with confirmed breast cancer: Rapid onset – 3 – 6 mo • Erythema > 1/3 breast • Edema (peau d’orange) • Often warm breast, pain • Breast enlargement – often without a mass • Highly metastatic: 35% metastasis at presentation Clinical Presentation - IBC
  • 5. Clinical Diagnosis of IBC • Tumor emboli in dermal lymphatics without classical signs is not considered IBC • The presence of dermal lymphatic invasion is not necessary for the diagnosis of IBC
  • 6. “Trimodality” Therapy: Importance of pCR Primary Systemic Therapy Mastectomy + Axillary LN Dissection Radiation to Chest Wall and Regional LN Adjuvant Endocrine Rx (HR+) +/or Trastuzumab (HER2+) Nakhlis 2016 Overall survival 86% 51% Time to tumor recurrence 79% 33%
  • 7. Retrospective Studies of Preoperative Chemotherapy for IBC No. IBC Chemotherapy RR Median Survival Italy 68 CAF or CEF / CMF pCR: 3% 4 yr. U Penn 52 CMF +/- CAF pCR: 12% NR France 120 FEC-HD pCR: 15% 5 yr. British Columbia 308 CT v intensive CT (+ T) pCR: 28% v 33% 3.2 yr. MD Anderson 240 FAC v FAC + T pCR: 10% v 25% 3.4 v 4.3 yr Primary chemotherapy backbone = anthracycline and taxane
  • 8. Dose-Dense versus Conventional Preoperative Chemotherapy (AGO-1) – Overall ≠ IBC • 668 patients with locally advanced breast cancer • Overall group benefitted from intensive chemotherapy: • Improved pCR – 18% vs 10% • Improved time to disease recurrence • Improved overall survival Untch M JCO 2009; 27:2938 • 100 IBC • No difference with intensity of chemotherapy: • No difference in pCR – 12% vs 10% • No difference in time to disease recurrence • No difference in overall survival ≠
  • 9. pCR Rates in SWOG 0012: Standard AC versus “Continuous” AC Georgiana K. Ellis et al. JCO 2011;29:1014-1021 • 356 Overall vs 111 IBC (31%) • Overall: no difference in outcome • Higher pCR in IBC with continuous dosing of chemotherapy – 27% vs 13%
  • 10. Finding Therapeutic Targets in IBC •HER-2 •Angiogenesis •JAK2-STAT3
  • 11. Finding Therapeutic Targets in IBC •Targeting HER-2 •Angiogenesis •JAK2-STAT3
  • 12. NOAH – IBC Experience 64% v 24% 74% v 44% 5-YR EFS 5-YR OS Doxorubicin 60mg/m2 → Paclitaxel 150mg/m2 q21d x 3 Paclitaxel 175mg/m2 q21d x 4 CMF x 3 Subset Analysis • 61 / 228 pts with IBC, HER2+ • pCR = 48 % with trastuzumab •13% without trastuzumab Gianni L. Lancet Oncol 2014 15:640
  • 13. Anti-HER2 Therapy Trypheana (13/225 = 6% IBC) FEC+HP x 3 →T+HP x 3 (N=73) FEC x 3 → T+HP x 3 (N=75) TCH+P x 6 (N=77) IBC 5(7%) 4(5%) 4(5%) tpCR 41(56%) 41(55%) 48(64%) NeoSphere (29/417 = 7% IBC) T+D (N=107) T+D+P (N=107) T+P (N=107) P+D (N=96) IBC* 7 (7%) 10 (9%) 7 (7%) 5 (5%) tpCR (all) 23 (22%) 42 (40%) 12 (11%) 17 (18%) 5y –DFS 81% 84% 80% 75% Gianni Lancet Oncol 2012;13:25-32; Schneeweiss Ann Oncol 2013;2278-84; Gianni Lancet Oncol 2016; Gianni Lancet Oncol 2012; Boussen, JCO 2010; Untch Lancet Onc 2012. Investigating lapatinib Regimen Number enrolled pCR MDACC Lapatinib + paclitaxel 32 3/17 (18%) GeparQuinto EC→D (L v H) 82/620 =13% IBC 23% v 30% (p=0.04) Odds ratio IBC = 0.72 (NS)
  • 14. Run In Phase – Day 1 week 1 (breast biopsy #1) Pertuzumab IV 840 mg loading dose Trastuzumab IV 4 mg/kg loading dose Treatment Phase – Day 8 week 2 (breast biopsy #2) Trastuzumab IV 2mg/kg weekly and paclitaxel 80 mg/m2 IV weekly x 16 weeks. Day 21 week 4 Continue trastuzumab and paclitaxel as above and begin pertuzumab 420 mg IV every 21 days for 5 doses Modified radical mastectomy (assess residual disease) Post-operative Treatment: Doxorubicin 60 mg/m2 IV and cyclophosphamide 600 mg/m2 IV every 3 weeks x 4 cycles* Followed by trastuzumab 6 mg/kg and pertuzumab 420 mg every 21 days x 8 months** (loading dose given first after AC completed) Radiation Therapy Endocrine therapy if HR+ *Optional **Metastatic disease (nodal disease only): continue on pertuzumab + trastuzumab until disease progression Primary Objective: pCR • Accept benefit if > 8/ 27 pts have pCR NCI-2013-01110, NCT0179619712-497; Genentech, IBC Network - sponsor Hypothesis: Can we limit the amount of chemotherapy and maximize the HER2- directed therapy in the treatment of HER2+ IBC ?
  • 15. Finding Therapeutic Targets in IBC •Targeting HER-2 •Angiogenesis •JAK2-STAT3
  • 16. Angiogenesis and Lymphangiogenesis in IBC • IBC makes its own blood supply and lymphatic supply throughout the breast • Increased expression of angiogenesis related genes • Increased expression of lymphangiogenesis related genes • Is this “encircling lymphovasculogenesis” or lymphovascular invasion ? Colpaert CG, Br J Ca 2003;88:718; Van der Auwera Clin Can Res 2005;11:7637
  • 17. Angiogenesis in IBC: Is it a Useful Target ? Addition of Anti-angiogenic Agents to Pre-operative Chemotherapy Treatment Number Stage pCR Median DFS (III) Correlatives SU5416, doxorubicin 17 III or IV 0 32 mo DCE/MRI – (Kep) – 58% (p=0.033) Bevacizumab, docetaxel, doxorubicin 21 (1 LABC) III or IV 1 (5%) 25.3 mo DCE-MRI – (Ktrans) – 34% (p=.003) BEVERLY-1 (FEC(B) x 4 → D(B) x 4) 100 III 19 (19%) 53 mo CTC not associated with pCR BEVERLY-2 (FEC(B) x 4 → D(B+H) x 4) 52 III 33 (64%) NA CTC not associated with pCR Overmoyer CCR 2007; Wedam JCO 2006; Bertucci 2016; Pierga 2012
  • 18. Eribulin and Normalization of Vasculature Region of Interest (ROI) Ktrans (1/min/1000) Pre-Eribulin Post-Eribulin (d 8) #1 ROI 78.1 115.2 #2 ROI 47.5 71.4 • Eribulin effects on mice: • Improves blood flow to inside of tumor • Increased overall tumor blood flow • Changes in expression of genes for blood vessel formation and cancer survival • In IBC – investigate eribulin’s effect on tumor blood flow • Also investigate expression on genes for blood vessel formation and cancer survival 2 1 Agoulnik Vasc Cell 2014.; Funahashi Cancer Sci 2014; Yoshida Br J Cancer 2014.; Dezso PLoS One 2014.; Overmoyer SABCS 2016. 2 1
  • 19. Pre-treatment breast biopsy #1 Eribulin x 1 (cycle 1 day 1) Breast biopsy #2: 1 wk after eribulin (cycle 1 day 8) Eribulin q 3 wks x 3 cycles dd AC q 2 wks x 4 cycles Mastectomy (harvest residual tumor) Radiation therapy + endocrine therapy Imaging subset study Pre-treatment breast DCE-MRI 1 wk after eribulin (c1,d8) breast DCE- MRI Eribulin 1.4mg/m2 IV d1,d8 q21d x 4 cycles Doxorubicin 60 mg/m2 + cyclophosphamide 600 mg/m2 IV q2w x 4 cycles Overview • Primary Objective: pCR rate • Two-stage design: • Reject if pCR is < 15% • Accept if pCR > 30% • > 2/16 pCR – go forward • Accept benefit if > 5/ 25 pts have pCR NCI-2016-00329, NCT0262397215-292; Eisai-sponsor
  • 20. Finding Therapeutic Targets in IBC •Targeting HER-2 •Angiogenesis •JAK2-STAT3
  • 21. Slides curtesy of Kornelia Polyak MD, PhD
  • 22. N=64 (50 +) Ruxolitinib x 7 days (N=32) Ruxolitinib x 7d + Paclitaxel x 1 wk (N=32) Paclitaxel x 12 weeks (N=16) Ruxolitinib + Paclitaxel x 12 weeks (N=16) Ruxolitinib + Paclitaxel x 11 weeks (N=32) dd doxorubicin/cyclophosphamide x 4 cycles (N=64) Modified radical mastectomy Radiation therapy Pre-treatment biopsy #1 Post-run-in biopsy #2 Primary: Pharmacodynamic Secondary: Clinical TBCRC 039 - SCHEME Sponsored by Incyte, and Inflammatory Breast Cancer Research Foundation
  • 23. Primary Systemic Therapy for IBC: Beginning the Journey • IBC is inoperable at the time of diagnosis, therefore initial therapy with “systemic treatment” is indicated. • IBC is relatively chemo-resistant, therefore identifying therapeutic targets is critical. • We must focus our efforts on designing clinical trials specifically for IBC • Inclusion of IBC patients into LABC trials will dilute the interpretation of outcome • Incorporate translational components • Identify biologic markers that confirm the diagnosis, not just rely on “clinical features” that are not consistent.